Doron Debbie - Nextage Therapeutics Independent Director
| MCTC Stock | ILA 64.00 2.30 3.47% |
Director
Mr. Doron Debbie was appointed Independent Director at Micromedic Technologies Ltd effective May 2, 2019. His work experience includes the following roles Owner and Chief Executive Officer of Sigma Health Care, Founder and CoChief Executive Officer of MAC VC, External Director at Israel Post, Partner and Director at Avgady Group and Director at Capital Nature and Terrogence. He holds a BS degree in Industrial Engineering and Management Sciences from Ben Gurion University, a MBA degree, majoring in Finance and Marketing, from Tel Aviv University and a has attended an International MBA course at INSEAD, France. since 2019.
| Age | 57 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Phone | 972 73 2753450 |
| Web | http://www.m-medic.com |
Nextage Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3684) % which means that it has lost $0.3684 on every $100 spent on assets. This is way below average. Nextage Therapeutics' management efficiency ratios could be used to measure how well Nextage Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | DIRECTOR Age | ||
| Daniel Zellinger | Mobile Max M | N/A | |
| Gideon Amihood | Mobile Max M | 79 | |
Management Performance
| Return On Asset | -0.37 |
Nextage Therapeutics Leadership Team
Elected by the shareholders, the Nextage Therapeutics' board of directors comprises two types of representatives: Nextage Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nextage. The board's role is to monitor Nextage Therapeutics' management team and ensure that shareholders' interests are well served. Nextage Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nextage Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Meir Yoeli, Chief Executive Officer | ||
| Itai BarNatan, Chief Officer | ||
| Yifftach Biel, Deputy Vice President - Finance | ||
| Yael Glickman, VP Devel | ||
| Doron Debbie, Independent Director |
Nextage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nextage Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.37 | |||
| Profit Margin | (2.30) % | |||
| Operating Margin | (9.71) % | |||
| Shares Outstanding | 2.27 M | |||
| Shares Owned By Insiders | 22.39 % | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | (91.98) X | |||
| Price To Book | 4.68 X | |||
| Price To Sales | 26.11 X | |||
| Revenue | 297 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| GM | General Motors | |
| CRM | Salesforce |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nextage Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Nextage Stock analysis
When running Nextage Therapeutics' price analysis, check to measure Nextage Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nextage Therapeutics is operating at the current time. Most of Nextage Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nextage Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nextage Therapeutics' price. Additionally, you may evaluate how the addition of Nextage Therapeutics to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |